Ferguson (Dean, School of Biological Sciences, University
of Manchester) noted that fetal wounds heal without the scarring that in the non-embryo causes adverse functional, growth and cosmetic sequelae. Investigation of the cellular and molecular basis of fetal healing showed a marked reduction in the levels of transforming growth factors pI and 2 (TGFp-I and 2).
Scarring was markedly reduced and the dermal architecture was almost completely regenerated by the intradermal application of neutralizing antibodies to TGF-pI and 2 at the time of and shortly after wounding". Exogenous addition of TGFf:I-3 produced a similar result. TGFps are secreted in an inactive form and activated by a complex protease cascade which involves binding of the latent TGFp molecule at the mannose-6-phosphate/IGF2 receptor; mannose-S-phosphate proved also to be an effective antiscarring agent. It is hypothesized that there has been phylogenetic optimization for speed of healing at the expense of the quality of the final repair. Professor 1 H Korn (Boston University School of Medicine, USA) spoke on endothelial cells (EC), mast cells and fibroblasts. ECs control many aspects of vascular homoeostasis and can produce growth factors and other soluble mediators capable of modulating fibroblast properties. Systemic sclerosis (SSc) fibroblasts produce cytokines which could alter EC phenotype. Fibroblast communication with immune cells is mediated by both direct cell contact and soluble cytokines. Direct contact depends on the interaction of adhesion ligands, principally intercellular adhesion molecule I (ICAM-I) with fibroblasts and the P2integrin LFA-I (COlla, CDI8) with lymphocytes. Very early in SSc increased leukocyte extravasation results from enhanced adhesion molecule expression; soluble forms of these and other endothelium-specific molecules in plasma attest to continuing endothelial activation. Mast cells accumulate at sites of fibrosis. Mast-cell-derived cytokines, including tumour necrosis factor-a (TNF-a), are marked stimulants to ICAM-I and vascular cell adhesion molecule I (VCAM) expression by endothelial cells. Other mast cell products including tryptase may also be important in both inflammatory and fibrotic diseases. Studies into the mechanism of accumulation of mast-cells and of their role in fibrosis are continuing 2 ,3. Studies concentrating on EC-induced modulation of fibroblast properties have employed conditioned media transfer and co-culture to show that EC can alter fibroblast proliferation rate, cell density at confluence and collagen production: the increased collagen production by SSc fibroblasts is suppressed and they achieve a greater confluent density than control cells.
Fibroblasts from both normal and diseased tissue are heterogeneous: synthesis of collagen and other cell products varies considerably in clones derived from a single source and among individual cells. Immune cell products may affect fibroblast metabolism in disease states by altering the resident population. There are data to suggest that SSc fibroblasts contain an increased proportion of high-collagenproducing cells. Fibroblast heterogeneity can also be demonstrated by examining clonal expression of surface antigens identified by monoclonal antibodies. The concept of a mechanism of 'clonal selection' or clonal overgrowth is supported by studies showing an alteration in expression of such antigens by SSc fibroblasts 4 .
In 'Pulmonary and cardio-vascular diseases' Dr R du Bois (Royal Brompton & National Heart Hospital, London), stated that EC products are present in increased amounts in the lower respiratory tracts of patients with fibrosing alveolitis (FA), resulting in the recruitment to disease sites of inflammatory cells. Macrophages 'orchestrate' the process, two key macrophage-derived cytokines being TNF and interleukin-S (IL-8), the most potent of the naturally occurring neutrophil chemoattractants and activators. There is greater up-regulation of both IL-8 (primarily due to an increase in the numbers of cells) and TNF-a (due to both an increased number of cells and increased production from each cell) than in controls. Messenger RNA for IL-8 is present only in alveolar macrophages from SSc patients who have fibrosis, whereas TNF mRNA can be isolated from lavage cells obtained from patients without diffuse lung diseases.
Previous work has shown a class II MHC link with fibrosis in SSc. The haplotype HLA-DR 3/52a, particularly in association with the presence of the Scl-70 autoantibody, is associated with a 16.7-fold excess risk of lung fibrosis, but no linkage is apparent between this class II haplotype and a bias in T-cell antigen receptor repertoire at disease sites. However, the haplotype is associated with a deletion in the region of a number of important pro-inflammatory genes, including the TNF cluster. Several polymorphisms have now been identified within this cluster region and it is intriguing to speculate that the association of this haplotype with fibrosis in SSc may actually be defining polymorphisms of the TNF gene which result in differences in function. Further studies are addressing this. The definition of appropriate treatment strategies will be helped by research focusing on a possible genetic predisposition to fibrosis.
Professor M Rabinovitch (Hospital for Sick Children, Toronto, Canada) in her paper 'Pulmonary hypertension and fibrosis' said that degradation of elastin was an early feature associatedwith pulmonary vasculardiseaseand that the presence of high elastase activity suggested a pivotal role for this enzyme. Elastase appears to be related to the serine protease adipsin; inhibition of elastase activity with serine protease inhibitors reduces both the severity of pulmonary hypertension and the progression of vascular disease. Elastase liberates active growth factors from the extracellular matrix. An interaction between cytokines and elastin peptides in inducing the glyccprotein fibronectin was demonstrated in coronary artery smooth muscle cells of animals with heterotopic heart transplants. Elastin peptides appear to up-regulate the induction of fibronectin by IL-1{1 by unmasking IL-1 receptors. Fibronectin appears to play key roles in inducing transendothelial trafficking of T-cells which perpetuate the immune-inflammatory reaction and in the vascular smooth muscle cell migration that contributes to neointimal formation. Coronary arteries following cardiac transplantation undergo accelerated neointimal formation. Immune inflammatory mechanisms of arterial disease invoke both elastase activity and fibronectin production, apparently cvtokinc-mediated", Professor B de Crombrugghe (Texas, USA) in 'Collagen expression' said that increased synthesis of type I collagen and other extracellular matrix components by affected fibroblasts is a hallmark of SSc. The regulatory mechanisms of the type I collagen genes have been examined by a variety of experimental approaches including transgenic mice and the DNA transfection of cultured cells. Mouse studies with various segments of the promoter of the pro« l (I) collagen gene support the notion that separate cellspecific cis-acting elements control its activity in type I collagen producing cells, while studies with the gene for the prolX 2(I) collagen chain showed a temporal and spatial correlation between the activity of a 2000 bp promoter and the presence of extracellular TGF-fi1, suggesting that TGFfil participates in the activation of this gene during embryonic development. Based on this and other work, a two-step model has been proposed for the activation of the genes in cells that produce type I collagen. First a cellspecific displacement of nucleosome takes place, then the binding to the promoter of ubiquitous transcription factors (UTF)j the presence of these UTF at the promoter results in high-level expression of the gene. In cells in which the type I collagen genes are inactive, displacement of nucleosomes would not take place and the UTF would not bind to the proximal promoter. We speculate that the far-upstream cell-specific enhancer in the proIX2(I) gene participates in nucleosome displacement at the proximal promoter of the gene. Further progress will depend on the identification of the cell-specific transcription factors which allow activation of these genes in the various type I collagen producing cells and on understanding the mechanisms by which cytokines alter the activities of both the cell-specific factors and the UTF controlling these genes 7 .
Recent work at the University of Bergen, said Professor K Rubin (University ofUppsala, Sweden) in 'Collagen-binding PI integrins', indicates that the collagen-binding PI integrins IXIPI and 1X2fil playa central role in the early oedematous phases of inflammation, and also that platelet-derived growth factor (PDGF) counteracts decreases in the interstitial fluid pressure and thus oedema formation in vivo. Using fibroblast-mediated collagen gel contraction as a model, it has also been shown that PDGF stimulates integrin activity. In a follow-up of earlier experiments in which it was shown that SSc fibroblasts do not respond normally to culturing in a native collagengel, the role of collagen-bindingfil integrins as potential regulators of fibroblast collagen synthesis is being studied",
In 'TNF and metalloproteinase' Dr A Gearing (British Biotechnology Ltd) stated that compounds combining matrix metalloproteinase and TNF inhibition are effective in animal models of arthritis and multiple sclerosis, and represent a novel approach to therapy. Synthetic hydroxamate-bascd metalloproteinase inhibitors are potent and specific inhibitors of the release from human and rodent cell linesand peripheral blood leucocytes of the pro-inflammatory cytokine TNF-IX. TNF-IX processing was unaffected by captopril, phosphoramidon or inhibitors of serine, aspartic and cysteine proteases and the production of other cytokines was not inhibited by metalloproteinase inhibitors", joe Kewin and Roger Hutchinson (North Derbyshire) described the closure of four institutions serving their area and the development of a wide variety of community living options. They emphasized that in the real world people have special needs which must be carefully defined in order to access the best available resources in integrated and specialist services.
Professor David Felce (Wales) traced the evolution of the 'ordinary life' model from the Brooklands Experiment carried out by Professor Jack Tizard, through the Wessex experiment and Andover Evaluation to the Nimrod and King's Fund models. Outcome data from research into such services comes from the All Wales Strategy. As judged from most outcome indicators high standards of care are hardest to achieve in people with severe learning disability, though our understanding of what they need continues to improve. The need to structure staff activity to provide the opportunities and support whereby people with limited skills can participate in the full range of ordinary activities has emerged as paramount. However, the Supported Living movement is directing attention to such issues as how groupings and staff support are determined, how residents can be accorded normal rights of self determination, and how the service fits into a wider context of natural supports and community resources. The implications of these two perspectives for the design of services, capable of providing desirable lifestyles for all service users, were discussed. Professor Felce concluded that attention to detail across a wide range of issues which define the environmental context and day-to-day organization, are what determine a successful residential service.
In discussion, the question of relative costs of different patterns of care was raised and Professor Felce mentioned a
